Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008.

Lonza Group stays busy making active ingredients. Spun off by Switzerland's former industrial giant Alusuisse Lonza Group (Algroup), Lonza Group is focused mostly on research and production for pharmaceutical and chemical firms. It is a contract manufacturer of the advanced intermediates and active ingredients used in drugs. Lonza also is active in biotechnology: It uses microbial fermentation and biotransformation to produce fine chemical intermediates and is involved in mammalian cell culture research. It also produces organic fine chemicals and performance chemicals (biocides and oleochemicals).

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Alnylam Pharmaceuticals, Inc. company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. Its lead RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, it reported positive results from its Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In April 2008, it initiated a second Phase II human clinical trial, which is, as of December 31, 2008, ongoing, to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV. As of December 31, 2008, it formed collaborations with Cubist Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd., for the development and commercialization of products for RSV.

Matrixx Initiatives, Inc., through its subsidiaries, engages in the development, production, marketing, and sale of over-the-counter (OTC) healthcare products. It offers Zicam Cold Remedy nasal pump, a homeopathic nasal gel that reduces the duration and severity of the common cold; Zicam Cold Remedy Swabs for consumers, who dislike nasal sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C, and Zicam Cold Remedy RapidMelts + Vitamin C and Echinacea, which are oral cold remedy products that deliver a dose of ionic zinc to the oral mucosa. The company also provides Zicam Allergy Relief, a homeopathic nasal gel formula to control allergy symptoms for sufferers of hay fever and upper respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for relief of nasal congestion and sinus pressure; and Zicam Sinus Relief that provides the benefit of the product with the aromatic strength of a cooling menthol/eucalyptus blend. In addition, it offers Zicam Cough Spray products to deliver cough relief and soothe throat irritation, including Zicam Cough Max, a liquid spray formulation that provides relief. Further, the company offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms; and Xcid, a creamy antacid product. It sells products directly to food, drug, mass market, and wholesale warehouse retailers in the United States, as well as to distributors that sell to retail establishments under the Zicam, Nasal Comfort, and Xcid brands.

Immtech Pharmaceuticals, Inc. company was founded in 1984 and is based in New York, New York. mmtech Pharmaceuticals, Inc. focuses on the discovery and development of drugs to treat infectious diseases worldwide. The company involves in drug discovery and development programs for hepatitis C and malaria; and provides aromatic cationic pharmaceutical compounds. It also offers assistance to healthcare companies seeking to conduct clinical trials, and manufacture and/or distribute pharmaceutical products in China. In addition, the company involves in investing in metal and mineral assets, primarily tin assets in China.

CEO Marc Coucke co-founded Omega Pharma NV company in 1987. Omega Pharma's first product was generic shampoo, which it sold to pharmacies. Omega Pharma NV is a Belgium-based provider of healthcare products and services for the pharmacies and other medical sectors. The Company specializes in the development, marketing and sales of health and personal care products, which can be obtained by the end-consumer without medical prescription (over the counter or OTC products). Omega Pharma NV consists of five business units, and is engaged in the provision of consumer-oriented medicines and healthcare products. It is composed of Omega Pharma Belgium, Omega Pharma France, Omega Pharma Northern Europe, Omega Pharma Southern Europe and Omega Pharma Rest of the World. As of December 31, 2008, the Company operated in over 30 countries, including most of the European countries, as well as Australia, New Zealand and Argentina.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

INC Research is a contract research organization (CRO) that specializes in conducting clinical trials for drugs targeting cancer, infectious diseases, and central nervous system disorders. It also has a division devoted to pediatrics. Its services include scientific and medical consulting, study monitoring, project management, and regulatory support services. The CRO operates in more than 30 countries around the globe. Its DataSpectrum subsidiary helps researchers capture and manage clinical trial data. The company was formed in 1998 as a result of the merger between the Neuroclinical Trials Center and the Integrated Neuroscience Consortium.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.